Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria

Completed · Phase 2 · Has a placebo group

Conditions studied: Mycobacterium Infections, Nontuberculous

In brief

The purpose of this study is to evaluate the efficacy, safety and tolerability of 84 days of daily dosing of 590 mg of LAI versus placebo in patients with treatment refractory NTM lung disease. The first part of the study is the 84-day double-blind phase to evaluate the primary and secondary endpoints.

Key facts

Study ID

NCT01315236

Run by

Insmed Incorporated

People needed

90

Starts

2012-04-19

Expected to finish

2015-06-18

Last updated by the study team

2019-08-21

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Birmingham, Alabama, United States
• Study site — Stanford, California, United States
• Study site — Denver, Colorado, United States
• Study site — Washington D.C., District of Columbia, United States
• Study site — Gainesville, Florida, United States
• Study site — Miami, Florida, United States
• Study site — Tampa, Florida, United States
• Study site — Kansas City, Kansas, United States
• Study site — Bethesda, Maryland, United States
• Study site — Rochester, Minnesota, United States
• Study site — New York, New York, United States
• Study site — Chapel Hill, North Carolina, United States
• Study site — Cleveland, Ohio, United States
• Study site — Portland, Oregon, United States
• Study site — Philadelphia, Pennsylvania, United States
• Study site — Charleston, South Carolina, United States
• Study site — Tyler, Texas, United States
• Study site — Milwaukee, Wisconsin, United States
• Study site — Hamilton, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.